Posted by Michael Wonder on 04 Mar 2025
FDA files Corcept’s new drug application for relacorilant as treatment for patients with hypercortisolism
3 March 2025 - FDA assigns a PDUFA target action date of 30 December 2025.
Corcept Therapeutics today announced that the US FDA filed its new drug application submission for its proprietary, selective cortisol modulator, relacorilant to treat patients with endogenous hypercortisolism (Cushing’s syndrome).
